Answers are grounded in this paper and cite their sources.
Review examines genetic influences on migraine treatment efficacy and explores new therapies.
Introduction: Migraine and cluster headaches are common primary headache disorders that substantially impair quality of life and increase healthcare burden. Treatment efficacy is often limited by variability in patient response, partly due to genetic factors. This review examines current acute and preventive therapies for migraine, with a focus on the influence of genetic variations. Methods: A literature review was performed on migraine pathophysiology, highlighting the trigeminovascular system and genetic contributions, particularly in familial hemiplegic migraine. Pharmacological interventions assessed included triptans, NSAIDs, anticonvulsants, antidepressants, calcium channel blockers, and emerging agents such as CGRP-targeted antibodies, gepants, and relaxants. The impact of genetic variations on drug efficacy, metabolism, and safety was also evaluated. Results: Genetic mutations affect both migraine susceptibility and therapeutic response. Triptans and NSAIDs remain first-line acute treatments, whereas anticonvulsants, antidepressants, and calcium channel blockers are commonly used for prophylaxis. Emerging CGRP-targeted therapies and gepants provide effective alternatives for patients with inadequate responses to conventional therapies. Genetic polymorphisms may modify pharmacokinetics and pharmacodynamics, supporting personalized treatment strategies. Discussion: The interconnection between genetics and pharmacological response underscores the importance of individualized treatment. While traditional therapies remain effective for many years, emerging agents provide options for refractory cases. Understanding genetic contributions can guide therapy selection, optimize efficacy, and minimize adverse effects. Conclusion: Migraine management relies on traditional pharmacological agents alongside emerging therapies targeting CGRP pathways. Genetic variations significantly influence disease susceptibility, treatment response, and safety. Integrating genetic insights into clinical practice can optimize therapeutic outcomes and advance personalized management strategies for patients with primary headache disorders.
No takes yet. Share an insight, caveat, or question.
Kamila et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: